Community Health Systems, Inc. (NYSE:CYH) Q3 2025 Earnings Call Transcript

Community Health Systems, Inc. (NYSE:CYH) Q3 2025 Earnings Call Transcript October 24, 2025

Operator: Good day, and welcome to the Community Health Systems Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded. I would now like to turn the conference over to Anton Hie, Vice President of Investor Relations. Please go ahead.

Anton Hie: Thank you, Betsy. Good morning, everyone, and welcome to Community Health Systems’ Third Quarter 2025 Conference Call. Joining me today on the call are Kevin Hammons, President and Interim Chief Executive Officer; and Jason Johnson, Senior Vice President, Chief Accounting Officer and Interim Chief Financial Officer. Before we begin, I’ll remind everyone this conference call may contain certain forward-looking statements, including all statements that do not relate solely to historical or current facts. These forward-looking statements are subject to a number of known and unknown risks as described in headings such as Risk Factors in our annual report on Form 10-K, and other reports filed with or furnished to the SEC.

Actual results may differ significantly from those expressed in any forward-looking statements in today’s discussion. We do not intend to update any of these forward-looking statements. Yesterday afternoon, we issued a press release with our financial statements and definitions and calculations of adjusted EBITDA and adjusted EPS. We’ve also posted a supplemental slide presentation on our website. All calculations we will discuss today exclude gains or losses from early extinguishment of debt, and impairment gains or losses on the sale of businesses. With that said, I’ll turn the call over to Kevin Hammons, President and Interim Chief Executive Officer. Kevin?

Kevin Hammons: Thank you, Anton. Good morning, everyone, and thank you for joining our third quarter 2025 conference call. Before we jump into discussing the quarter, I want to take a moment to thank the team here at CHS for the support they’ve shown me and others through the recent transition of senior leadership. It is gratifying to see our team’s confidence in the work we are doing here at CHS and their commitment to our future success. Over the past 90 days or so, since stepping into my new role as interim CEO, I’ve had the opportunity to visit several of our markets and speak with many of our hospital leadership teams, including operational, financial, clinical and service line leaders. It is always inspiring to see the folks who are providing high-quality care for our patients, and helps put into perspective how important our hospitals are to the people and communities they serve.

At CHS, we will remain focused on supporting our caregivers, physician partners and support teams to help ensure an exceptional health care experience for our patients. Next month, approximately 150 CEOs and CFOs from across the CHS network will gather for a leadership conference where we will discuss our vision for the future of the company and our ongoing commitment to investments in quality, improving both physician and patient experience, improving employee satisfaction, and achieving sustainable positive free cash flow. As I’ve shared with many on our team already, I’m very optimistic about the future of CHS and our opportunities to continuously improve the health care experience. To continue to improve our operational and financial performance and to create value for our investors through disciplined and proactive management of our business.

Now turning to the third quarter operating results. Our operating performance was in line with our updated expectations. And our reported results were further enhanced by the recognition of a $28 million gain from the settlement with some prior litigation, which reimbursed us for previously incurred expenses. Same-store net revenue for the third quarter improved 6% year-over-year. We were encouraged to see some improvement in payer mix on both a sequential and year-over-year basis as well, as realizing the incremental state directed payments from New Mexico and Tennessee when compared to the prior year. As we have done all year, we continue to grow our inpatient volume. However, similar to last quarter, the overall business mix remains more heavily skewed towards medical versus surgical cases.

And inpatient admissions were flat ahead of outpatient elective procedures. However, solid expense management across most categories helped drive slight margin expansion year-over-year, even when excluding the benefit from the legal cell. We continue to make targeted investments in advance our competitive position in many key markets during the quarter, including capacity and service line expansions, such as the acquisition of a vascular surgery practice and the relocation of a large OB/GYN practice onto our campus, both in Birmingham, Alabama. The addition of a new urology service line in Las Cruces, New Mexico, the addition of a new neurosurgery and spine program in Laredo, Texas and new robotic surgery programs in two of our New Mexico markets.

We are successfully recruiting physicians and advanced practice providers to our markets. At September 30, 2025, we had approximately 160 more employee physicians and APPs in our clinics than in the prior year. With the recent recruits and plan commencements in the fourth quarter and early next year, we should be favorably positioned as we enter 2026. In addition, we continue to improve our capital structure, further reducing our leverage to 6.7x, down from 7.4x at year-end ’24. Also as a reminder, during the quarter, we refinanced $1.74 (sic) [$1.743 billion ] of our Senior Secured Notes due 2027, through the offering of $1.79 billion of 2034 notes, thereby pushing out our nearest significant maturity to 2029. At this point, I want to introduce Jason Johnson, our Interim Chief Financial Officer.

And I’ll turn the call over to Jason to review the financial results in greater detail and discuss our updated guidance. Jason?

Jason Johnson: Thank you, Kevin, and good morning, everyone. For the third quarter, CHS delivered results generally consistent with expectations. The overall volume growth was in line with our updated guidance and with continued solid execution on controllable aspects of our business, the company achieved expansion in adjusted EBITDA margins, and remains on track for the full year. Adjusted EBITDA for the third quarter was $376 million, compared with $347 million in the prior year period, with a margin of 12.2%, increasing 100 basis points year-over-year. Results included $28 million from the receipt of a settlement of a legal matter recognized as nonpatient revenue. When excluding this amount, adjusted EBITDA was $348 million (sic) [ $376 million ] and margin was approximately 11.4%, up 20 basis points from the prior year period.

Please note that the nonpatient revenue related to legal settlement is excluded from the same-store metrics provided in our earnings release and supplemental materials. Same-store net revenue for the third quarter increased 6.0% year-over-year, again, driven primarily by rate growth as net revenue per adjusted admission was up 5.6% year-over-year. Same-store inpatient admissions increased 1.3% year-over-year, and adjusted admissions were up 0.3%. Same-store surgeries declined 2.2% and ED visits were down 1.3%. We were encouraged by the sequential volume performance coming out of the second quarter, which was better than our typical seasonal experience in the third quarter. However, as Kevin previously noted, we again experienced a divergence in inpatient surgeries, which were flat year-over-year.

And outpatient surgeries, which were down, reflecting continued pressure on consumer demand for elective procedure in our markets. Despite this environment, the company continued to perform well on cost controls, including labor costs. The year-over-year increase in average hourly rate was in line with our expectations and contract labor expense was down slightly on a year-over-year basis. We also performed well again on supplies expense, which were down year-over-year, and as a percentage of net revenue fell 20 basis points to 15.0% when excluding the $28 million legal settlement. While we acknowledge ongoing inflationary pressures and potential incremental upward pressure from tariffs on imported products and raw materials in future periods, we believe that opportunities remain as we stabilize and mature workflows under our ERP.

Medical specialist fees were $165 million in the third quarter up approximately 4% year-over-year on a same-store basis, and representing 5.4% of net revenue when excluding the legal settlement, which is generally consistent with recent quarters. We expect continued upward pressure on medical specialist fees in the fourth quarter and into next year, especially in radiology, while increased use of emerging or developing technology, including AI tools should eventually help on this front. Cash flows from operations were $70 million for the third quarter, and $277 million for the year-to-date. Cash flows from operations for the year-to-date as reported includes $126 million in outflows for taxes on gains on sales of hospitals, which are paid out of divestiture proceeds that are reported as investing cash flows.

When excluding these cash taxes on divestiture gains, our adjusted cash flows from operations were $403 million for the year-to-date, and adjusted free cash flows were slightly negative for the year-to-date. Based on our historical performance, in which the fourth quarter operating cash flows are typically the strongest of the year, we remain confident in our ability to achieve positive free cash flow for the full year of 2025 after adjusting for cash taxes paid on divestiture gain. In August, we refinanced substantially all of our 2027 maturities, using proceeds from an offering of $1.79 billion and 9.75% Senior Secured Notes due 2034, to redeem via a tender offer $1.743 billion, or 99%, of our outstanding 2027 Senior Secured Notes. As Kevin previously noted, leverage at quarter end was 6.7x, down from 7.4x at year-end 2024, and our next significant maturity is in 2029, providing ample runway to continue executing our strategic initiatives.

As expected, in October, we received $91 million in contingent cash consideration related to last year’s divestiture Tennova Cleveland. We also continue to expect the divestiture of our outreach lab asset to close later this quarter with proceeds of approximately $195 million, which will provide additional liquidity to fund growth investments or further reduce our leverage. Now moving on to our updated 2025 financial guidance. Based on our operating results through the first 9 months, along with the benefit from the legal settlement that was not contemplated in the previous guidance, we are tightening our adjusted EBITDA range for the full year 2025 to $1.50 billion to $1.55 billion. Consistent with our prior approach, this guidance does not contemplate any further divestitures beyond those announced, nor does it assume contribution from any new or pending supplemental payment programs.

This concludes our prepared remarks. So at this time, we will turn the call back over to the operator for Q&A.

Q&A Session

Operator: [Operator Instructions] The first question today comes from Brian Tanquilut with Jefferies.

Brian Tanquilut: Congrats on the quarter. Maybe, Kevin, as I think about volume performance, obviously, nice to see the positive trend in inpatient. But on the outpatient side, you still saw some weakness in surgeries and ER. Just any thoughts you can share with us in terms of what you’re seeing in terms of the recovery of volumes there? Or how are you guys thinking internally in terms of what that trajectory looks like? And maybe also the components of what outpatient is, and what you’re seeing in those buckets?

Kevin Hammons: Thanks, Brian. Absolutely. So as we called out in the second quarter, and as I believe we still saw in the third quarter, some of the economic headwinds, more the macroeconomics, the climate and consumer confidence seems to be the big headwind. And I think that continued on into the third quarter, particularly in some of our markets are experiencing some heavier or more softness economically than other markets. . And so we still believe that has been the primary driver of some of the softness now. As consumer confidence seems to be stabilizing, it’s bounced off its lows in the second quarter a little bit and seems to be improving. We are seeing some recovery, and I think that we experienced that where we saw some improvement in payer mix into the third quarter, and we’re certainly experiencing that in some of our markets.

So that gives us a little more confidence as the payer mix improves and people are feeling better. They’re starting to come back in for more procedures. Our — although we were still down on an outpatient elective surgery volume year-over-year, it was improved over second quarter. So we did see some improvement there. I’d also point out maybe that the immigration climate probably is affecting some of our markets still if you think about markets in Arizona, across Texas, primarily, there’s still probably a little bit of an overhang there where patient behavior, people are staying away from hospitals, at least on an elective basis more than we’ve seen in the past. Now we’re also experiencing, or noticing that, in our ER business. And many of those are uncompensated.

So where you’re seeing some lower volume and maybe why that hasn’t completely been noticed in our EBITDA generation is because some of that volume that we’re seeing lots of volume, particularly in the ERs and uncompensated care. And so that has not had an EBITDA — negative EBITDA impact on it.

Brian Tanquilut: That’s very helpful, Kevin. And then maybe just a follow-up question for me. How should we be thinking about your divestiture kind of plans or outlook for 2026?

Kevin Hammons: Yes, we’re still pursuing. Some divestitures were in some early conversations that — it’s too early at this point. We don’t know how far those will go. But certainly, we’re continuing to get some inbound interest. We are in some more advanced discussions on a couple of deals, which we think could be announced even later this year. But no agreements have been signed at this point. So nothing to report today that we are advancing some discussions…

Operator: The next question comes from A.J. Rice with UBS.

Albert Rice: First of all, I guess, you’re moving towards this year. It sounds like you think you’ll be free cash flow positive on a full year 2025 basis, assuming the fourth quarter comes in with a couple of hundred million positive for you. Is that — as you begin to move to a position where that’s ongoing going to be the case. Does that change your thinking on capital deployment, amount of CapEx you’re going to spend, other initiatives, maybe tuck-in deals with outpatient or other things? Any thoughts on that?

Kevin Hammons: Thanks, A.J. Absolutely, I think that it frees us up a little bit and does allow us to think, and be a little more strategic in terms of how we think about either deploying capital. It gives us some optionality of whether we use incremental free cash flows to further delever the company to — which in effect would have a virtuous cycle benefit because it reduced future cash flows. We could use it where there are opportunities for some tuck-in deals to spend capital more strategically in areas of things that we think could generate further EBITDA. So it does free stuff and should then again, create a little more of a virtuous cycle for us.

Albert Rice: Okay. And then, I mean it’s early, I know, but when you look at ’26 and you’re starting your budgeting process, et cetera. Are there headwinds or tailwinds that you would call out that we should keep in mind as we try to model ’26?

Kevin Hammons: Yes. I think I could point out a few things. Certainly taking into consideration the divestitures that we’ve completed this year, Lake Norman and ShorePoint early in the year, Cedar Park divestiture kind of midyear. We did recognize some prior year SVP for Tennessee that’s about $15 million to $20 million that we’ll have this year towards the settlement gain that we recognized this quarter. As I think about 2026, directionally, some of the things — Medicare rate increase will be strong for 2026. We potentially there’s a couple of other SVP programs out there in Georgia, Florida, Indiana, the rural health fund, which we don’t know, can’t quantify at this point, but that should be incrementally positive for us. And then we’re making — continue to make some growth investments. And as you just mentioned with positive free cash flow this year continue on into next year may allow us to further invest in incremental growth capital.

Jason Johnson: I might add, Kevin, this is Jason, that you might want to include that $28 million legal settlement this quarter. Exclude that from the jump off from the 2025.

Operator: The next question comes from Ben Hendrix with RBC Capital Markets.

Benjamin Hendrix: Just a quick question for Kevin and Jason in turn. Just a little bit more color on your early observations in your roles. Kevin, you mentioned you’ve visited some facilities, any surprises or anything out of expectation in your review of the platform? And then any initiatives you guys are looking at? You talked a little bit already about capital deployment. But anything in operations or balance sheet management that could kind of deviate from your prior practice?

Kevin Hammons: Thanks, Ben. I appreciate the question. I think the short answer is to say, I’m really excited about the direction of the company, and I’m confident that we have the right strategies and people in place to execute on our opportunities. We’ve had a — I believe, a very smooth transition of leadership. And I believe we’re already picking up momentum in a number of key areas. As I mentioned in my prepared remarks, we have taken the time to visit several local health systems. We’ve met with health system leaders and I think substantially all of our major markets already. They’re very enthusiastic about the progress we’re making. And I just — and becoming increasingly confident that our investments, our strategic priorities, and the resources that we’re appropriately laser-focused on those most important aspects of our business.

I think we’ll see some of that come to fruition here in the near term with a few areas. I’m highly focused on quality of care. So our quality, ratings, our patient and physician experience, employee satisfaction, and I won’t take my CFO hat on, and I’ll continue to be laser-focused on free cash flow and making sure we’ve made such great progress over the last, probably, 9 quarters in a row on free cash flow trending positively, now that we’re getting to kind of cross over from being negative to positive free cash flow. I think that’s going to give us a lot more opportunity. So as I think though about those kind of 5 priority areas for myself and the progress that we’re already making on quality and getting focused on the others. I think that will help really accelerate what we can do in the future.

Jason Johnson: Brian, this is Jason. Kevin alluded to as CFO hat so. I’m in the position of following the guy who’s still here. And Kevin put into place to focus on adjusted free cash flow in that virtuous cycle, and that’s — we’re continuing to make sure that we’re laser focused on that. So no change there. I do think about that, we got the ERP fully implemented earlier this year. So continuing to optimize that as a big focus. Evaluation of the most efficient use of proceeds from any divestitures, whether that’s investment in capital or deleveraging through debt repurchases. So from my standpoint, it’s just — I’ve been here with Kevin for a number of years. So I understand what his vision is financially and aligned with it and we’re continuing on.

Benjamin Hendrix: Great. Appreciate that. Just a quick follow-up to a prior comment. With the sequential surgical trend you saw from 2Q into 3Q, anything changing in the way we should think about typical 4Q elective seasonality?

Kevin Hammons: I do feel that with the improvement in payer mix in Q3, it gives me a little more confidence that Q4 could look more like the normal seasonal recovery. There was some concern that if commercial patients did not come back in Q3, and you get late in the year and people have not met their co-pay and deductible yes, they may put it off until early 2026. It’s looking less likely that, that will occur. But with the continued kind of headlines around health care and some uncertainty, we did not want to get ahead of ourselves in terms of guidance, or suggesting that it could be better. But I think we’re in a pretty good position coming into Q4. There’s also potentially an opportunity that people are concerned who have exchange insurance, about losing it.

There may be some more of that comes back in Q4. It’s a relatively small component of our net revenues, is less than 5% of our net revenues. So I don’t think it’s a real material needle mover for us, but it potentially could be a slight positive.

Operator: The next question comes from Andrew Mok with Barclays.

Andrew Mok: I think I want to just follow up on some of those encouraging volume trends. Were those trends you saw exiting 3Q, or at the start of 4Q? And from a category standpoint, what are you seeing? And is the payer mix improvement generally driven more by the employer-based coverage, or the ACA?

Kevin Hammons: So we saw the payer mix improvements really beginning early Q3 in July. So the — we saw that improvement throughout Q3. So I think our expectation would be that, that will likely continue into Q4. Now from a comp perspective, Q4 of 2024 was strong and particularly kind of the post-election period, we saw consumer confidence kind of spike in Q4 of last year. So we will have that to climb over. But all in all, directionally and sequentially, I would say that we should continue — or we expect that we could continue to see some improvement Q3 to Q4. In terms of where we’re seeing improvement in terms of the breakdown? It was primarily in commercially insured business, although we did see improvement in exchange as well. But again, the exchange business is a relatively small component of our overall net revenues.

Andrew Mok: Great. And on the government side of things, Indiana is one of your largest states, which I think has the large — one of the largest declines in state Medicaid enrollment to date. Are you seeing the impact of tighter Medicaid eligibility in states like Indiana impact your Medicaid volume results?

Kevin Hammons: We’ve not. We’ve not experienced any significant impact, specifically to Indiana from that.

Operator: The next question comes from Jason Cassorla with Guggenheim.

Jason Cassorla: Can you guys hear me?

Kevin Hammons: Yes Jason.

Jason Cassorla: Okay. Got it. I just wanted to touch quickly. I think you noted kind of thinking about 2026 and the favorable Medicare IPPS coming in. Obviously, the — we’re waiting on the final outpatient rule. But like as you think about — if the outpatient were to come in as proposed, like how do you think about the net of those two pieces as it relates to 2026? Were they largely offset each other? Or are there nuances from a Medicare rate perspective if the OPPS comes in as proposed?

Kevin Hammons: I would say with the proposed outpatient, but we know an inpatient proposed outpatient, I still think it’s a little net positive to 2026 over 2024. Sorry, 2025.

Jason Cassorla: Okay. Great. And maybe just more of a high-level question. On the ambulatory front, I know you have new access points opening up, including a few ASCs. But as you step back, can you just discuss your ambulatory strategy or remind us, help frame maybe what inning you’re in, in terms of building out those access points and how that’s helped your market share position? And anything else along those front would be very helpful.

Kevin Hammons: Sure. So we are — continue to look at access points. We’ve been investing in those for some time. I think each market — in our markets, each market is a little bit different. We’ve taken a little different strategy in those markets where we’ve had capacity constraints on the inpatient side. We have invested in more inpatient dollars, such as this past year, we opened up new towers in Knoxville, Tennessee, where we added, I believe, 58 beds, and we added a new patient tower in Foley, Alabama. Both of those markets, we had capacity constraints. Currently, we do not have any of those kind of larger construction projects on the inpatient side in flight. And so as we kind of move through ’25 into 2026, more of our dollars will be focused on the access points, whether that’s urgent care, freestanding EDs, ASCs, and so forth.

And so I think those are lower dollar. We can do more of them kind of for the same amount of capital. Now we have been opening 3 to 4 freestanding EDs per year. We have, I believe, 3 ASCs scheduled for opening this quarter here in 2025 — in the fourth quarter of 2025. We’ll probably target kind of 6 to 8 ASCs for next year in 2026 along with some additional freestanding EDs and possibly some urgent care centers. And then we’re always also acquiring clinics and hiring new doctors into our existing clinics as well.

Operator: The next question comes from Stephen Baxter with Wells Fargo.

Unknown Analyst: This is Mitchell on for Steve. Can you please highlight what drove the 5.6% growth in same-store revenue per admission, and kind of what you see as a sustainable rate there?

Jason Johnson: Steven, this is Jason. About 1/3 of that 5.6% improvement in same-store net revenue per AA is a result of the Tennessee and New Mexico state-directed payments programs that were approved in the second quarter. And then the rest of the improvement is payer mix related. And there is some offset. We did have a little bit lower acuity.

Kevin Hammons: I might — just to add in terms of kind of what’s sustainable. We think a mid-single-digit net revenue growth and net revenue per growth is a sustainable number. And between your Medicare rate increases our commercial rate increases, we expect acuity to recover going forward. Right now, there is some dilutive impact on the net revenue per AA with the softer outpatient surgeries, particularly orthopedic and cardiac surgeries, which have been areas of softness. But as those come back, we should see a lift in the net revenue per AA, just that they’re higher acuity services.

Operator: The next question comes from Josh Raskin with Nephron. Josh, your line is open. You may now ask your questions. We appear to have lost connection with Josh…

Joshua Raskin: I’m sorry, do you guys hear me?

Kevin Hammons: We can.

Joshua Raskin: Sorry. Can you speak to trends from payers around denials and underpayments, maybe just an update there and more importantly, around maybe the mitigation of those pressures? And I’m curious if you’re using any external vendors? Or is it all internal services on the RCM side and maybe any changes that have been there through the year?

Kevin Hammons: Sure. So we called out really third quarter last year and in 2024, a big spike in denials. And since that time, it’s stabilized. It is not really gotten any worse. But we continue to invest in our physician adviser program. We’re investing in some AI tools in terms of how we do denials with our internal revenue recycle team. We are using a combination of third-party vendors as well as internally developed products on that for purposes of our revenue cycle team. Our revenue cycle is managed internally with our own team that they do use a combination of products. So as we get better at it, I would say we’ve been able to kind of hold things stable, which would indicate that the payers are probably also denying more claims, but we’ve been more efficient or better at overturning some of those denials in order to kind of keep things status quo.

Joshua Raskin: Perfect. Perfect. That’s helpful. And maybe just a quick one. Flu season. It seems like off to a little bit of a slow start. I assume that’s contemplated in guidance, and I’d be curious if you guys are seeing any updates into October as we kind of move into flu season?

Kevin Hammons: Yes. It is contemplated in guidance, and we haven’t seen any big pickup yet in our facilities and the heavy flu. So at this point, I’m not sure we’ll — what we’ll see yet for the remainder of the quarter, but we have kind of taken that into consideration.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Mr. Hammons for any closing remarks.

Kevin Hammons: Thank you, everyone, for joining us on the call today. I want to close by reiterating my thanks for our team members at CHS for their commitments and confidence through the leadership transition as we approach the future together. If you have any additional questions, you can always reach us at (615) 465-7000. Have a good day, everyone.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.